OB/GYNs serve as vital confidants and trusted sources of information as patients navigate long-term breast cancer treatment, including its side effects. In this supportive role, a normal exam can turn into a candid conversation about side effects and their impact on quality of life.

Alison Cowan, MD, is one of these OB/GYNs. She understands the importance of patients with HR+, early-stage breast cancer talking to their oncologists about their concerns and options beyond 5 years.

Breast Cancer Index is the only guideline-recognized test that can predict if a woman with HR+ early-stage breast cancer is likely to benefit from extending endocrine therapy beyond year 5.

Alison Cowan is an OB/GYN and the former Medical Director for Hologic, Inc. Statements may reflect her personal views and interpretation. Visit breastcancerindex.com to learn more and for Intended Use and Limitations.

свернуть